<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1386">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769365</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS99-CT7-10</org_study_id>
    <nct_id>NCT01769365</nct_id>
  </id_info>
  <brief_title>Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection</brief_title>
  <official_title>Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <authority>Taiwan: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To simultaneously compare the efficacies of 7-day triple, 10-day sequential and 7-day
      quadruple therapies for H. pylori infection in Taiwan. Consecutive H. pylori-infected
      patients were randomly assigned to a 7-day standard triple therapy (pantoprazole,
      clarithromycin, and amoxicillin for 7 days), a 10-day sequential therapy (pantoprazole and
      amoxicillin for 5 days, followed by pantoprazole, clarithromycin and metronidazole for a
      further 5 days) or a 7-day quadruple therapy (pantoprazole, clarithromycin, amoxicillin and
      metronidazole for 7 days). The end point is to evaluate the effectiveness of Helicobacter
      pylori eradication rates between three groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the effectiveness of three H. pylori eradication
      regimens: 7-day standard triple therapy (pantoprazole, clarithromycin, and amoxicillin for 7
      days), 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by
      pantoprazole, clarithromycin and metronidazole for a further 5 days) and 7-day quadruple
      therapy (pantoprazole, clarithromycin, amoxicillin and metronidazole for 7 days) in Taiwan.

      A total of 306 subjects are enrolled into this study.

      H. pylori-infected patients are randomized to a 7-day standard triple therapy, a 10-day
      sequential therapy, or a 7-day quadruple therapy. Eradication efficacy is assessed by a
      follow-up endoscopy with rapid urease test and histological examination eight weeks after
      the H. pylori therapy. The eradication rates of three groups will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Eradication</measure>
    <time_frame>at the 6th week after the end of anti- H. pylori therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate eradication outcome by endoscopy urease test and histology or urea breath test</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>7-day quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10-day sequential therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7-day standard triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-day quadruple therapy</intervention_name>
    <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days</description>
    <arm_group_label>7-day quadruple therapy</arm_group_label>
    <other_name>Pantoprazole, amoxicillin, clarithromycin, metronidazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-day sequential therapy</intervention_name>
    <description>pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days</description>
    <arm_group_label>10-day sequential therapy</arm_group_label>
    <other_name>sequential group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-day standard triple therapy</intervention_name>
    <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days</description>
    <arm_group_label>7-day standard triple therapy</arm_group_label>
    <other_name>pantoprazole, clarithromycin, amoxicillin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive H. pylori-infected outpatients, at least 20 years of age, with
             endoscopically proven peptic ulcer diseases or gastritis

        Exclusion Criteria:

          -  previous H. pylori-eradication therapy

          -  ingestion of antibiotics, bismuth, or proton pump inhibitors within the prior 4 weeks

          -  patients with allergic history to the medications used

          -  patients with previous gastric surgery

          -  the coexistence of serious concomitant illness (for example, decompensated liver
             cirrhosis, uremia)

          -  pregnant women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping-I Hsu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung city</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 6, 2015</lastchanged_date>
  <firstreceived_date>January 14, 2013</firstreceived_date>
  <firstreceived_results_date>September 6, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Ping-I (William) Hsu, M.D.</investigator_full_name>
    <investigator_title>Chief of Division of Gastroenterology; Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori infection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We surveyed patients who visited the gastroenterological clinic of Kaohsiung Medical University Hospital (KMUH), Kaohsiung Veteran General Hospital (KVGH). A total of 307 H. pylori-infected patients were randomly assigned to triple (n=103 ) or sequential (n = 102) or concomitant (n = 102) therapies.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>7-day Quadruple Therapy</title>
          <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
7-day quadruple therapy: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days</description>
        </group>
        <group group_id="P2">
          <title>10-day Sequential Therapy</title>
          <description>pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
10-day sequential therapy: pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days</description>
        </group>
        <group group_id="P3">
          <title>7-day Standard Triple Therapy</title>
          <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
7-day standard triple therapy: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>7-day Quadruple Therapy</title>
          <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
7-day quadruple therapy: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days</description>
        </group>
        <group group_id="B2">
          <title>10-day Sequential Therapy</title>
          <description>pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
10-day sequential therapy: pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days</description>
        </group>
        <group group_id="B3">
          <title>7-day Standard Triple Therapy</title>
          <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
7-day standard triple therapy: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="102"/>
                <measurement group_id="B2" value="102"/>
                <measurement group_id="B3" value="103"/>
                <measurement group_id="B4" value="307"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="74"/>
                <measurement group_id="B2" value="68"/>
                <measurement group_id="B3" value="69"/>
                <measurement group_id="B4" value="211"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="34"/>
                <measurement group_id="B3" value="34"/>
                <measurement group_id="B4" value="96"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53.85" spread="12.31"/>
                <measurement group_id="B2" value="54.96" spread="12.00"/>
                <measurement group_id="B3" value="56.08" spread="14.00"/>
                <measurement group_id="B4" value="54.88" spread="12.73"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
                <measurement group_id="B2" value="50"/>
                <measurement group_id="B3" value="41"/>
                <measurement group_id="B4" value="132"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="61"/>
                <measurement group_id="B2" value="52"/>
                <measurement group_id="B3" value="62"/>
                <measurement group_id="B4" value="175"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Taiwan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="102"/>
                <measurement group_id="B2" value="102"/>
                <measurement group_id="B3" value="103"/>
                <measurement group_id="B4" value="307"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Eradication</title>
        <description>Evaluate eradication outcome by endoscopy urease test and histology or urea breath test</description>
        <time_frame>at the 6th week after the end of anti- H. pylori therapy</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>7-day Quadruple Therapy</title>
            <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
7-day quadruple therapy: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days</description>
          </group>
          <group group_id="O2">
            <title>10-day Sequential Therapy</title>
            <description>pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
10-day sequential therapy: pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days</description>
          </group>
          <group group_id="O3">
            <title>7-day Standard Triple Therapy</title>
            <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
7-day standard triple therapy: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="102"/>
                  <measurement group_id="O2" value="102"/>
                  <measurement group_id="O3" value="103"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Eradication</title>
            <description>Evaluate eradication outcome by endoscopy urease test and histology or urea breath test</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="102"/>
                  <measurement group_id="O2" value="100"/>
                  <measurement group_id="O3" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>7-day Quadruple Therapy</title>
          <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
7-day quadruple therapy: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days</description>
        </group>
        <group group_id="E2">
          <title>10-day Sequential Therapy</title>
          <description>pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
10-day sequential therapy: pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days</description>
        </group>
        <group group_id="E3">
          <title>7-day Standard Triple Therapy</title>
          <description>pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
7-day standard triple therapy: pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was performed in a single country</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ping-I Hsu</name_or_title>
      <organization>Kaohsiung Veterans General Hospital</organization>
      <phone>+886-7-3422121 ext 8233</phone>
      <email>pihsu@isca.vghks.gov.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
